Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate

Fig. 2

Change in fatigue, depression, and cognition scores by geographic region. aP < .0001 for Latin America vs. Canada/Western Europe at final follow-up. bP < .0001 for change from baseline. cP < .0001 for change from baseline. dP = .0030 for change from baseline. eP = .0024 for change from baseline. CES-D Centre for Epidemiologic Studies Depression, MFIS Modified Fatigue Impact Scale, PASAT Paced Auditory Serial Addition Test, WE Western Europe

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us